Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)

被引：0
|
作者：
Delaloge, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Tedesco, K. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Blum, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Goncalves, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Lubinski, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Efrat, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Osborne, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Lebedinsky, C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Tercero, J. C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Holmes, F. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] US Oncol, New York Oncol Hematol, Albany, NY USA
[3] Baylor Sammons Canc Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[4] Inst J Paoli I Calmettes, F-13009 Marseille, France
[5] Int Hereditary Canc Ctr, Szczecin, Poland
[6] Kaplan Med Ctr, Rehovot, Israel
[7] PharmaMar Colmenar Viejo, Madrid, Spain
[8] US Oncol Res, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1010
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)
    Tedesco, K. L.
    Blum, J. L.
    Goncalves, A.
    Lubinski, J.
    Osborne, C. R. C.
    Lardelli, P.
    Tercero, J. C.
    Florez, A.
    Holmes, F. A.
    Delaloge, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC)
    Tedesco, K. L.
    Blum, J. L.
    Goncalves, A.
    Lubinski, J.
    Ben-Baruch, N.
    Osborne, C. R.
    Lardelli, P.
    Tercero, J. C.
    Holmes, F. A.
    Delaloge, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] EFFECTS OF RESVERATROL ON TRIPLE NEGATIVE (ER-, PR-, HER2-) BREAST CANCER CELLS
    Mangum, Carla
    Cameron, Joseph A.
    Herbert, Brittney-Shea
    FASEB JOURNAL, 2008, 22
  • [4] Real-world clinical and economic burden associated with hospitalization in metastatic triple-negative (ER-/PR-/HER2-) breast cancer.
    Tan, Amie
    Han, Xu
    Near, Aimee
    Tse, Jenny
    Preger, Luciana
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Translational correlates, including outcome for patients with ER-/PR-/HER2-(triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC)
    Thome, S.
    Hobday, T.
    Hillman, D.
    Aubry, M.
    Lingle, W.
    Reinholz, M.
    Graham, D.
    Flynn, P.
    Moreno, A.
    Perez, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
    Blum, Joanne L.
    Goncalves, Anthony
    Efrat, Noa
    Debled, Marc
    Conte, Pierfranco
    Richards, Paul D.
    Richards, Donald
    Lardelli, Pilar
    Nieto, Antonio
    Cullell-Young, Martin
    Delaloge, Suzette
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (02) : 295 - 302
  • [7] A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer
    Joanne L. Blum
    Anthony Gonçalves
    Noa Efrat
    Marc Debled
    Pierfranco Conte
    Paul D. Richards
    Donald Richards
    Pilar Lardelli
    Antonio Nieto
    Martin Cullell-Young
    Suzette Delaloge
    Breast Cancer Research and Treatment, 2016, 155 : 295 - 302
  • [8] Comparison of patients with "triple negative" breast cancer (ER-, PR-, HER2-) in a cohort of 1052 patients treated in a single institution between 1999 and 2007
    Kantelhardt, E. J.
    Pauli, N.
    Grosse, R.
    Vetter, A.
    Holzhausen, H. J.
    Strauss, H. G.
    Thomssen, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S255 - S255
  • [9] PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.
    Poggio, Francesca
    Bruzzone, Marco
    Ceppi, Marcello
    Conte, Benedetta
    Martel, Samuel
    Maurer, Christian
    Tagliamento, Marco
    Viglietti, Giulia
    Del Mastro, Lucia
    De Azambuja, Evandro
    Lambertini, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Evaluation of microRNA expression profiles in triple-negative (ER, PR and Her2/neu) breast cancer patients with and without germ-line BRCA mutations
    Erturk, E.
    Cecener, G.
    Egeli, U.
    Tunca, B.
    Tezcan, G.
    Gokgoz, S.
    Tolunay, S.
    Tasdelen, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S95 - S95
12345